Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Yonatan Malca Biography and Net Worth

Director of Entera Bio

Mr. Malca has served as a member of the Board of Directors since 2011. Mr. Malca currently serves as a CEO and Director of D.N.A Biomedical Solutions Ltd., one of our principal shareholders, a position he has held since 2010. Mr. Malca also serves as a director of Arko Holdings Ltd., an Israeli public company. Mr. Malca also serves on the board of directors of a number of private companies, including as chairman of the board of directors of Cardioart Technologies LTD, a medical device company. Mr. Malca received a B.A. and an M.A. from Bar Ilan University.

How do I contact Yonatan Malca?: The corporate mailing address for Mr. Malca and other Entera Bio executives is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. Entera Bio can also be reached via phone at (722) 532-7151 and via email at [email protected]. Learn More on Yonatan Malca's contact information.
Has Yonatan Malca been buying or selling shares of Entera Bio?: Yonatan Malca has not been actively trading shares of Entera Bio within the last three months. Most recently, on Thursday, January 13th, Yonatan Malca bought 7,232 shares of Entera Bio stock. The stock was acquired at an average cost of $2.74 per share, with a total value of $19,815.68. Learn More on Yonatan Malca's trading history.
Who are Entera Bio's active insiders?: Entera Bio's insider roster includes Yonatan Malca (Director), Ron Mayron (Director), and Ramesh Ratan (CFO). Learn More on Entera Bio's active insiders.
Are insiders buying or selling shares of Entera Bio?: In the last year, Entera Bio insiders bought shares 4 times. They purchased a total of 81,067 shares worth more than $56,274.47. The most recent insider tranaction occured on January, 12th when Director Haya Taitel bought 9,500 shares worth more than $9,405.00. Insiders at Entera Bio own 8.9% of the company. Learn More about insider trades at Entera Bio.
Information on this page was last updated on 1/12/2024.

Yonatan Malca Insider Trading History at Entera Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/13/2022	Buy	7,232	$2.74	$19,815.68

Yonatan Malca Buying and Selling Activity at Entera Bio

Entera Bio Company Overview

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $1.99

$1.95

$2.29

50 Day Range

MA: $1.58

$0.85

$2.98

2 Week Range

Now: $1.99

$0.52

$3.35

Volume

300,731 shs

Average Volume

212,725 shs

Market Capitalization

$57.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7